Placebo for Depemokimab Injection
Sponsors
Glaxosmithkline Research & Development Limited
Conditions
Hypereosinophilic Syndrome (HES)Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
Phase 3
A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
Active, not recruitingCTIS2023-510019-20-00
Start: 2022-07-13Target: 80Updated: 2026-01-19
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES)
RecruitingCTIS2023-510346-25-00
Start: 2022-09-01Target: 36Updated: 2025-12-10